{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+matching+with+Sitagliptin", "query": { "intervention": "Placebo matching with Sitagliptin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+matching+with+Sitagliptin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T13:58:00.345Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01549964", "title": "Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glycemic Control" ], "interventions": [ { "name": "Fasiglifam (TAK-875)", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 916, "start_date": "2012-04", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-06-02", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 58, "location_summary": "Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01549964" }, { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT01081834", "title": "The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 678, "start_date": "2010-03", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01081834" }, { "nct_id": "NCT01552694", "title": "Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation", "Macrophage Infiltration", "Cardiovascular Disease" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2012-10", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-05-08", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552694" }, { "nct_id": "NCT01619332", "title": "Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Type II Diabetes" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "LEZ763", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 220, "start_date": "2012-03", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 6, "location_summary": "Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01619332" }, { "nct_id": "NCT01289990", "title": "Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin 100mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2705, "start_date": "2011-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-07-15", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289990" }, { "nct_id": "NCT01488279", "title": "Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pre-diabetes", "Impaired Fasting Glucose", "Impaired Glucose Tolerance" ], "interventions": [ { "name": "Dexamethasone 2.5 mg and Sitagliptin 100 mg", "type": "DRUG" }, { "name": "Dexamethasone 2.5 mg and placebo tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2012-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-03-12", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 1, "location_summary": "South Burlington, Vermont", "locations": [ { "city": "South Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01488279" }, { "nct_id": "NCT02202161", "title": "A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "GSK2330672", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "30 Years to 64 Years" }, "enrollment_count": 70, "start_date": "2014-08-27", "completion_date": "2015-01-30", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 4, "location_summary": "Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202161" }, { "nct_id": "NCT03115112", "title": "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Bexagliflozin", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo for sitagliptin", "type": "DRUG" }, { "name": "Placebo for bexagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theracos", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2017-10-12", "completion_date": "2018-10-31", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 10, "location_summary": "Lincoln, California • Long Beach, California • San Dimas, California + 7 more", "locations": [ { "city": "Lincoln", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Dimas", "state": "California" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03115112" }, { "nct_id": "NCT01106677", "title": "The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Metformin immediate release", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1284, "start_date": "2010-05", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-09-27T13:58:00.345Z", "location_count": 45, "location_summary": "Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106677" } ] }